What Petrosino Assvisors aren't telling their Weal
Post# of 1418
(Total Views: 234)
Posted On: 03/09/2022 10:32:41 AM
What Petrosino Assvisors aren't telling their Wealth Inhibitor clients
Todos Market Cap is sitting at $25M right now
Through the first nine months of 2021, revenue was $7,77M. Let's say very conservatives revenue comes in at a nice even $10M for 2021. That puts the company at a 2.5 multiple of revenue. If they get the money owed to them, than it could be a 2x multiple.
Pick another company. Inventiva SA's (NASDAQ: IVA) popped up with news yesterday so lets use that.
The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.
The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety and efficacy of lanifibranor combined with empagliflozin for non-cirrhotic NASH and Type 2 Diabetes (T2D).
LEGEND is expected to recruit a total of 63 non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with T2D.
Huh, only 63 patients? Petrosino Assvisors & Friends thought you should have 10,000s in all phase II trials. Oh and this is just a POC and not even of double blind BTW
For the 2021 fiscal year, Inventiva's revenues amounted to €4.2 million compared to €0.4 million for 2020 primarily due to the payment to the Company of €4.0 million for a milestone reached at the end of 2021, and received on January 31, 2022, following the launch by AbbVie of the Phase IIb clinical trial with cedirogant in the fourth quarter of 2021.
R&D expenses doubled for the fiscal year ended December 31, 2021 €48.4 million compared to €23.7 million for the same period in 2020
General and administrative expenses (G&A) amounted to €11.2 million for the fiscal year ended December 31, 2021, an increase of 31% compared to €8.5 million
The Company’s net loss stood at €49.6 million as of December 31,2021 compared to €33.6 million as of December 31, 2020
Implementation of an At-The-Market (“ATM”) program in the United States for the sale up to $100 m of ADS
Inventiva's Market Cap $460M
So their revenue is 1/2 of Todos, cap is nearly 20 times that of Todos
In fact, their cap is 100x revenue and it's down a bit
They are ringing up cash out of the ATM
Burning through money
$50M net loss
10's of millions of debt and liabilities
I could go on but you probably get the point
Oh, and they have no commercial products
This was just picking a company at random
Let's see, if Todos was valued at x100 revenue, that would be $1B
So when someone says the stock is going to trips. I can see those zeros
Triple trips +$1,000,000,000
Not today, nor tomorrow, but the value right now is beginning manipulated on the OTC. You can see it when you look at the trades. You can easily see it when you look at other stocks
Earnings release is 3 weeks or less away. Won't have long to wait.
Do you own DD and don't get it off a messageboard or Petrosino Assvisors & Wealth Inhibitors.
Todos Market Cap is sitting at $25M right now
Through the first nine months of 2021, revenue was $7,77M. Let's say very conservatives revenue comes in at a nice even $10M for 2021. That puts the company at a 2.5 multiple of revenue. If they get the money owed to them, than it could be a 2x multiple.
Pick another company. Inventiva SA's (NASDAQ: IVA) popped up with news yesterday so lets use that.
The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.
The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety and efficacy of lanifibranor combined with empagliflozin for non-cirrhotic NASH and Type 2 Diabetes (T2D).
LEGEND is expected to recruit a total of 63 non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with T2D.
Huh, only 63 patients? Petrosino Assvisors & Friends thought you should have 10,000s in all phase II trials. Oh and this is just a POC and not even of double blind BTW
For the 2021 fiscal year, Inventiva's revenues amounted to €4.2 million compared to €0.4 million for 2020 primarily due to the payment to the Company of €4.0 million for a milestone reached at the end of 2021, and received on January 31, 2022, following the launch by AbbVie of the Phase IIb clinical trial with cedirogant in the fourth quarter of 2021.
R&D expenses doubled for the fiscal year ended December 31, 2021 €48.4 million compared to €23.7 million for the same period in 2020
General and administrative expenses (G&A) amounted to €11.2 million for the fiscal year ended December 31, 2021, an increase of 31% compared to €8.5 million
The Company’s net loss stood at €49.6 million as of December 31,2021 compared to €33.6 million as of December 31, 2020
Implementation of an At-The-Market (“ATM”) program in the United States for the sale up to $100 m of ADS
Inventiva's Market Cap $460M
So their revenue is 1/2 of Todos, cap is nearly 20 times that of Todos
In fact, their cap is 100x revenue and it's down a bit
They are ringing up cash out of the ATM
Burning through money
$50M net loss
10's of millions of debt and liabilities
I could go on but you probably get the point
Oh, and they have no commercial products
This was just picking a company at random
Let's see, if Todos was valued at x100 revenue, that would be $1B
So when someone says the stock is going to trips. I can see those zeros
Triple trips +$1,000,000,000
Not today, nor tomorrow, but the value right now is beginning manipulated on the OTC. You can see it when you look at the trades. You can easily see it when you look at other stocks
Earnings release is 3 weeks or less away. Won't have long to wait.
Do you own DD and don't get it off a messageboard or Petrosino Assvisors & Wealth Inhibitors.
(3)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼